Literature DB >> 1934660

The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study.

G Banfi1, M Moriggi, E Sabadini, G Fellin, G D'Amico, C Ponticelli.   

Abstract

In this retrospective study we report the outcome of 59 adults with idiopathic focal-segmental glomerulosclerosis (FSGS) and nephrotic syndrome (NS) treated with corticosteroids and/or immunosuppressive drugs. Twenty-seven patients were initially treated with corticosteroids alone for 9.3 +/- 8 months; nineteen patients received corticosteroids and immunosuppressive agents associated or every other month for 5.5 +/- 4 months; thirteen patients received either azathioprine or cyclophosphamide alone for 25 +/- 27 months. At the end of a mean follow-up of 75 +/- 51 months, 35 patients (60%) were in complete (CR) or partial (PR) remission, 6 (10%) were stable and 18 (30%) had either chronic renal failure (CRF) or end-stage renal failure (ESRF). Out of 36 patients (61%) initially responsive to therapy, 30 (83%) obtained CR, 4 (11%) PR, one (2.7%) developed CRF and one (2.7%) ESRF. Only 10 of the responders (28%) attained remission within 8 weeks of treatment. Out of the 23 (39%) patients originally resistant to therapy, only one (4%) had CR, 6 (26%) remained unchanged, 6 (26%) developed CRF and 10 (43%) ESRF. The presence at initial renal biopsy of interstitial fibrosis was the only feature which could predict a poor renal outcome. These data show that prolonged treatment of FSGS can obtain sustained remission of the disease and improved renal survival in a consistent proportion of adult patients which would be considered refractory to a two-month course with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934660

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  29 in total

1.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

3.  Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.

Authors:  Furong Li; Chunxia Zheng; Yongzhong Zhong; Caihong Zeng; Feng Xu; Ru Yin; Qi Jiang; Minlin Zhou; Zhihong Liu
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

Review 4.  Minimal change disease and idiopathic FSGS: manifestations of the same disease.

Authors:  Rutger J Maas; Jeroen K Deegens; Bart Smeets; Marcus J Moeller; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2016-10-17       Impact factor: 28.314

5.  Renal allograft loss due to renal vascular thrombosis in the US pediatric renal transplantation.

Authors:  Chia-Shi Wang; Larry A Greenbaum; Rachel E Patzer; Rouba Garro; Barry Warshaw; Roshan P George; Pamela D Winterberg; Kavita Patel; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2019-05-26       Impact factor: 3.714

6.  Primary focal segmental glomerular sclerosis in children: clinical course and prognosis.

Authors:  Kyung Hoon Paik; Bum Hee Lee; Hee Yeon Cho; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Dong-Kyu Jin; Kyung Chul Moon; Yong Choi
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

7.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

Review 8.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

9.  Ponticelli regimen in idiopathic nephrotic syndrome.

Authors:  U Das; K V Dakshinamurty; N Prasad
Journal:  Indian J Nephrol       Date:  2009-04

Review 10.  [Treatment of glomerulonephritis].

Authors:  T Risler; N Braun; C M Erley
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.